Literature DB >> 1198069

Detection of IgG aggregates or immune complexes using solid-phase C1q and protein A-rich Staphylococcus aureus as an indicator system.

C Farrell, H Sogaard, S E Svehag.   

Abstract

A radioimmunoassay for detection of C1q-binding IgG aggregates and antigen-IgG antibody complexes is described. The assay makes use of solid-phase C1q and 32p-labelled protein A-rich Staphylococcus aureus as an indicator system. Both 19S and heavier IgG aggregates that fixed C1q were detected. The sensitivity of the assay permitted detection of heavy (19-25S) IgG aggregates at a concentration of 8 mug/ml or less. The results indicated that detection of IgG in this assay is dependent on the degree of IgG polymerization and the molar ratio between the solid-phase C1q and the IgG polymers. Albumin-anti-albumin complexes, preformed at equilibrium with antibody to antigen molar ratios of 2:1 to 3:1 and at antigen concentrations of 25 to 40 mug/ml, were also detectable using the described radioimmunoassay.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1198069     DOI: 10.1111/j.1365-3083.1975.tb02675.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

1.  Studies on circulating soluble immune complexes of the liver disease. 1. Inhibition assay of polyclonal rheumatoid factor binding to IgG-sepharose.

Authors:  J Narumoto; T Arima; K Kunishi; T Yasuhara; K Suwaki; H Shimomura; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1979-12

Review 2.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

3.  Circulating immune complexes in Lyme arthritis. Detection by the 125I-C1q binding, C1q solid phase, and Raji cell assays.

Authors:  J A Hardin; L C Walker; A C Steere; T C Trumble; K S Tung; R C Williams; S Ruddy; S E Malawista
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

4.  Prevalence and persistence of C1q binding activity in healthy subjects.

Authors:  S M Walker; S F Al Khateeb
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

5.  Purification of the subunit Clq from the first component of equine complement.

Authors:  T L McDonald; D Burger
Journal:  Immunology       Date:  1979-07       Impact factor: 7.397

6.  Activity of antibodies recovered from immune complexes of ovarian cancer patients.

Authors:  P M Lutz; J R Dawson
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Studies on circulating soluble immune complexes of the liver disease. 6. Comparative studies of 125I-pRF inhibition assay, 125I-Clq inhibition assay and 125I-Clq binding assay.

Authors:  J Narumoto
Journal:  Gastroenterol Jpn       Date:  1981

8.  Binding of immunoglobulin G aggregates and immune complexes in human sera to Staphylococci containing protein A.

Authors:  J S McDougal; P B Redecha; R D Inman; C L Christian
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

9.  Studies on circulating immune complexes of the liver disease. 4. Clq binding activity.

Authors:  T Arima; J Narumoto; H Shimomura; K Suwaki; K Kunishi; T Yasuhara; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1980

10.  Studies on circulating immune complexes of the liver disease. 3. Conditions for Clq binding assay and low molecular weight Clq reactants.

Authors:  T Arima; J Narumoto; H Shimomura; K Suwaki; K Kunishi; T Yasuhara; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.